Elsevier,
Sleep and Sport: Physical Performance, Mental Performance, Injury Prevention, and Competitive Advantage for Athletes, Coaches, and Trainers, 2024, pp 137-164
This content aligns with Goal 3: Good Health and Goal 9: Industry, Innovation and Infrastructure by discussing the relationship between sleep and mental health in athletes and exploring the infrastructure in place to manage athlete mental health.
This study aimed to examine relationships among eating frequency, timing and time window, and cognitive performance and novel Alzheimer disease (AD) biomarkers in cognitively healthy and mildly cognitively impaired middle-aged and older adults. It concluded that an eating pattern characterized by less frequent eating and/or by earlier times is present in individuals with worse cognitive performance. The results shed light on the relevance of temporal eating patterns as potential early markers of behavioral or metabolic changes related to AD pathology.
This article provides evidence that disruption of the intestinal mucosal barrier contributes to sarcopenia and functional dependence in patients with AD. RE may be an effective therapy to strengthen the intestinal mucosal barrier, reduce sarcopenia, and improve functional performance in patients with AD.
This review provides a comprehensive overview of both conventional and novel therapeutic strategies for Alzheimer's disease (AD), highlighting traditional Acetylcholinesterase (AChE) inhibition and emerging approaches such as Butyrylcholinesterase (BChE) inhibition, Tau Protein inhibitors, and COX-2 inhibition, while also exploring the roles of endocannabinoids, cholesterol-lowering drugs, and microRNA, alongside novel research tools and current clinical trials, to offer a consolidated resource for advancing AD treatment and research.
This study found that Alzheimer’s disease neuropathological change (ADNC) is associated with gene expression changes that may impair cholesterol biosynthesis in neurones but not astrocytes, whilst levels of cortical cholesterol show a weak relationship to dementia status.
Every year, 10 million people develop dementia, most commonly Alzheimer's disease (AD), and despite limited therapies and no prevention for cognitive decline, this review offers a neuroimmunological perspective on AD progression, focusing on the role of the NLRP3 inflammasome, its brain triggers, and the potential impact of various NLRP3 inhibitors currently under investigation in preclinical and clinical trials.
The study discusses the latest developments in Alzheimer’s disease treatment, with a focus on monoclonal antibodies and aptamers. It covers the current state of therapies, recent drug approvals, and future perspectives on immunotherapeutic strategies.
This article discusses the impact of methionine oxidation on clusterin function in Alzheimer's disease, highlighting the elevated levels of MetO-clusterin in human and mouse brains affected by the disease, and how this oxidation compromises clusterin's chaperone function, potentially exacerbating beta-amyloid toxicity in Alzheimer's pathology.
This Article supports SDG 3 by assessing the effectiveness of a hepatitis B model of care in Australia, suggesting that the model, involving primary health care, could be rolled out nationally or internationally. The authors suggest that the model could have positive implications particularly for low-income and middle-income countries.
This Article supports SDG3 by evaluating the cost-effectiveness of integrating simplified hepatitis C virus testing with HIV PrEP treatment among men who have sex with men.
